There is currently no satisfactory model allowing analysis of dose-effect relationships of BCR-ABL proteins in human hematopoietic cells. To study comparatively the proliferative, differentiative and anti-apoptotic actions of different levels of BCR-ABL proteins in the context of the same cellular background, we have introduced the BCR-ABL gene into the GM-CSF-dependent pluripotent human cell line UT-7. Individual clones expressing BCR-ABL were analyzed by Western blots. After normalization to equivalent levels of endogenous ABL protein, 14 clones always grown in GM-CSF were found to express low but variable levels of BCR-ABL whereas two clones selected in the absence of GM-CSF expressed very high levels of BCR-ABL. All low-level BCR-ABL expressing clones exhibited a behavior similar to that of the GM-CSF-dependent parental cells as they ceased to proliferate upon growth factor deprivation and showed a strong proliferative response upon GM-CSF addition. One out of 14 clones showed progressive GM-CSF independence during culture over several weeks and was found to have a significant increase of BCR-ABL expression at that time. The resistance of this clone (E8-2) to different apoptotic stimuli was found to be increased as compared to its low BCR-ABL-expressing counterpart (E8-1) and similar to that observed in clones with very high levels of BCR-ABL (UT-7/9 and UT-7/11) which were totally resistant to apoptotic stimuli. When injected into nude mice, parental UT-7 cells and clones with low-level of BCR-ABL were not tumorigenic over 10 weeks of observation whereas UT-7 clones with high levels of BCR-ABL (UT-7/9, UT-7/11 and UT-7/E8-2) induced aggressive tumors in 2-4 weeks with a significant correlation between the amount of BCR-ABL protein and the rate of tumor growth. In conclusion, the establishment of an in vitro and in vivo CML model using UT-7 cells suggests for the first time in human cells, that the fully transformed phenotype induced by BCR-ABL requires high levels of BCR-ABL expression. These findings suggest that variable levels of BCR-ABL in primary patient cells could also be responsible for the different phenotypic features seen in chronic and acute phases of CML, such as the differentiation ability induced by growth factors. Leukemia (2000) 14, 662-670.
Introduction
BCR-ABL fusion gene, the molecular hallmark of the Philadelphia translocation (Ph 1 chromosome) induces growth factor independence and inhibition of apoptosis in experimental systems including mouse and human cell lines. [1] [2] [3] It has been established that BCR-ABL triggers a variety of molecular events inside the target cell with activation of several molecular pathways such as RAS, PI-3K and CRK-L. [4] [5] [6] It has not been established, at this time, if these abnormalities have any rel- evance with regard to human CML in which there have been conflicting reports with regard to the anti-apoptotic effects of BCR-ABL. [7] [8] [9] [10] Similarly, although BCR-ABL gene transfer induces growth factor independence in growth factor-dependent cell lines, human hematopoietic progenitors bearing the BCR-ABL translocation as assessed by PCR or FISH analyses are not growth factor-independent and present only subtle abnormalities such as Epo-independent erythroid colony growth 11 in the presence of Steel factor. 12 Anti-apoptotic activities of BCR-ABL have been shown to be reverted by inhibition of the tyrosine kinase activity of BCR-ABL. 13 In the murine Ba/F3 cell line, a dose-response effect of the BCR-ABL has been shown for resistance to apoptotic agents but not with regard to growth factor independence. 14 The effects of different levels of BCR-ABL protein in the context of the same cellular background in terms of growth factor independence, phenotypic changes induced under the influence of growth factors and response to apoptotic stimuli have not been established so far. BCR-ABL expression in the context of the human MO7e cell line has been found to induce growth factor independence 3 but no data were available in this work with regard to the effects of different levels of BCR-ABL. Expression of BCR-ABL in murine cell lines leads to a rapid growth factorindependent behavior 14 which is not seen in patients with chronic phase CML. 11, 12 In order to generate a model for human CML, we have chosen the pluripotent human cell line UT-7 as a target for BCR-ABL gene transfer. This cell line is GM-CSF-dependent for its growth and survival and shows erythroid as well as megakaryocytic and eosinophilic differentiation potentials. 15 BCR-ABL gene transfer was accomplished using retroviral vectors and individual clones expressing very high or low levels of BCR-ABL protein were amplified allowing therefore the assessment of the effects of different levels of BCR-ABL protein expression in the context of the same cellular background. Our results show that low-level BCR-ABL expressing UT-7 clones remain growth factordependent both for their proliferation and survival. Resistance to apoptotic signals such as growth factor deprivation or etoposide is obtained only in clones expressing high levels of BCR-ABL protein whereas growth factor-dependent clones do not resist apoptotic stimuli. A significant correlation is also found between the tumorigenicity of UT-7 clones in nude mice and the levels of BCR-ABL expression.
Materials and methods

UT-7 cell line
This cell line, generously provided by Dr Komatsu, 15 was grown in RPMI medium containing 10% FCS and 10 ng/ml of rhGM-CSF. Cells were split three times per week at the concentration of 10 5 cells/ml.
BCR-ABL retroviral vectors
The two retroviral vectors used in this study were MP-ZEN p210 BCR-ABL and MSCV-p210-BCR-ABL. The MP-ZEN plasmid was kindly provided by Dr S Cory to Dr RK Humphries's laboratory (Terry Fox Laboratory, Vancouver, Canada) where we have generated the amphotropic packaging cell line. 16 MPZEN p210 vector contains in the U3 region of its 3Ј LTR sequences derived from the myeloproliferative sarcoma virus (MPSV) and has no selectable marker. 17 In order to facilitate the selection of the retrovirus producing cell lines, we have generated the MSCV-p210 vector construct based on the MSCV-Neo 2.1 (murine stem cell virus) retroviral vector generously provided by Dr RH Hawley (University of Toronto, Canada). The MSCV vectors have been designed to obtain an improved gene transfer in embryonal stem cells and have been shown to lead to efficient expression of heterologous genes in hematopoietic cells. 18 To construct MSCV p210, the p210 cDNA (contained in the pK562 plasmid and provided by Dr RK Humphries) was excised by EcoRI and subcloned into the EcoRI site of the MSCV-Neo 2.1 using standard molecular techniques. CsCl-purified plasmids were used for gene transfer experiments.
BCR-ABL gene transfer
Gene transfer in the UT-7 cell line has been found to be very difficult using standard gene transfer techniques such as electroporation. To transfer the BCR-ABL-p210, we have generated an amphotropic retrovirus packaging cell line, Am 12-MPZEN p210. 16 Am 12 cell line provided by Dr A Bank's laboratory (Columbia University) was transfected with MPZen p210 cDNA (20 g) along with 1 g of pM1cNeo plasmid. G418-resistant clones were selected and screened for BCR-ABL gene expression and their ability to transfer BCR-ABL and growth factor-independent behaviour into the IL-3-dependent murine Ba/F3 cell line according to a previously described protocol. 17 BCR-ABL gene transfer into UT-7 was accomplished using a co-culture protocol. The UT-7 cell line (10 5 cells/ml) was co-cultured in the presence of an 80% confluent packaging cell stroma along with GM-CSF (10 ng/ml) and polybrene (4 g/ml) for 72 h. At the end of the infection period, cells were removed from the dishes, washed and cloned in methylcellulose in the absence of GM-CSF. Sixteen individual clones were selected for their growth factor independence and amplified in the absence of GM-CSF. Out of these 16 clones, we were able to amplify only two clones expressing BCR-ABL (UT-7/9 and UT-7/11). In order to facilitate selection of transfectant clones and not to use growth factor independence as the only means for selection, we have used MSCV-p210 Neo which was transfected into UT-7 cells using a lipofection procedure according to the protocol provided by the manufacturer (Gibco-BRL, Paisley, UK). After lipofection, medium was changed the following day and cells were cloned in methylcellulose containing 10 ng/ml rhGM-CSF and 1 mg/ml of G418. A polyclonal stock was also obtained by selection of cells in liquid cultures. Individual G418-resistant clones were taken from methylcellulose cultures, expanded in the presence of GM-CSF and G418 and characterized by the use of Northern and Western blots for BCR-ABL expression. BCR-ABL expression was demonstrated in 14 individual clones always grown in GM-CSF and three of these (UT-7/E8, UT-7/F1, UT-7/G6) as well as a subclone of UT-7/E8 showing a progressive increase of BCR-ABL level Leukemia proteins (designed as E8-2) were chosen for further characterization. All clones were maintained in culture for a limited period of time and new aliquots were thawed from the initial stocks with determination of BCR-ABL expression levels in each new aliquot. As a control for these experiments, we also used in addition to the parental cell line, the MSCV-Neo vector without the BCR-ABL insert.
Western blotting
Exponentially growing UT-7 clones were lysed (5 × 10 6 cells in 100 l) in a sample buffer containing 0.125 mm Tris-HCl (pH 6.8), 4% SDS, 20% glycerol and 10% ␤-mercaptoethanol. Total proteins corresponding to 10 6 cells of each fraction (20 ml of the initial lysate) were then separated on a 7.5% SDS-polyacrylamide gel in a Tris-glycine buffer (25 mm Tris, 192 mm glycine and 0.1% SDS). After electrophoresis, proteins were electroblotted on to nitrocellulose filters (100 V; 90 min at 4°C). The blot was then blocked in 5% milk in PBS Tween 1× at room temperature, and incubated overnight with an anti-abl antibody (Ab3, Oncogene Science, Cambridge, MA, USA) diluted in blocking solution. Bands of 210 kDa and 145 kDa corresponding to the transfected BCR-ABL p210 and the endogenous ABL protein, respectively, were visualized with the enhanced chemiluminescence detection system (ECL; Amersham Corporation, Arlington Heights, IL, USA) according to the manufacturer's protocol. Bands obtained in Western blots were scanned using a densitometer (Hoefer, San Francisco, CA, USA) and the integrated areas of the peaks were used to calculate BCR-ABL:c-ABL ratio in each lane. To detect the cleavage of poly-(ADP-ribose)-polymerase (PARP) by Western blotting, cell extracts were prepared as above and after electroblotting, the filters were hybridized with a rabbit anti-PARP antibody used at a dilution of 1:5000 as recommended by the manufacturer (Boehringer Mannheim GmbH, Germany).
Cell proliferation and survival assays
Cell proliferation assays were performed using standard thymidine incorporation techniques in 96-well plates. 10 4 cells were cultured for 48 h with and without growth factors at 37°C and then incubated with 3 H-TdR (Amersham) for 18 h at a concentration of 2 Ci per well. Thymidine incorporation was determined using a Betaplate counter (LKB Wallac, St Quentin-en-Yvelines, France). MTT tests were performed in order to determine the responses of different transfectants to growth factors. Each test was performed in triplicate and the results were confirmed in at least three separate experiments.
Proliferative responses of high-and low-level BCR-ABL expressing clones
Proliferation and survival assays of UT-7/P (parental), UT-7-Neo cells, UT-7/9, UT-7/11, UT-7/E8, F1 and G6 were set up using five conditions: no growth factors, GM-CSF (10 ng/ml, R&D, Abingdon, UK), Epo (2 U/ml, R&D), TPO (10 ng/ml, Genzyme) and SCF (50 ng/ml, gift from Amgen). 10 4 cells were washed and cultured in triplicate in 96-well plates for 48-72 h before assessing the proliferation and survival either by MTT or thymidine proliferation tests.
Leukemia
Tumorigenicity assays
Exponentially growing parental UT-7 cells (3 × 10 6 cells per mouse) as well as UT-7 clones with high or low levels of BCR-ABL expression were injected subcutaneously to sublethally irradiated nude mice (4 Gy). The animals were maintained in the animal facility of the Institut Gustave Roussy and followed once a week for the appearance of tumors which were measured. After a period of 8-10 weeks, the animals with tumors were sacrificed and the tumors were analyzed by Western blot to determine the expression of BCR-ABL protein.
Induction of apoptosis
To induce apoptotic cell death in different cell lines, we used stimuli including serum deprivation, growth factor deprivation (GM-CSF) or etoposide. To determine the optimal concentration of etoposide in parental UT-7 cell line, preliminary experiments were performed using etoposide doses ranging from 2 g/ml to 30 g/ml. The parental cells as well as UT-7 clones expressing variable levels of BCR-ABL were then cultured for 20 h in the presence of different concentrations of etoposide before FACS analysis. To induce apoptosis by growth factor or serum deprivation, cells were washed twice in PBS and were grown in RPMI supplemented with Glutamax (Gibco) with or without addition of rhGM-CSF (10 ng/ml) for 48 h and subsequently analyzed using flow cytometry to determine the amount of apoptotic nuclei as a sub-G1 peak (see below).
Quantitative FACS-based assay for apoptosis
This assay was performed as described by Nicoletti et al. 19 Briefly, 2.5 × 10 6 UT-7 cells treated with several doses of etoposide (10-30 mg/ml for 20 h) or grown in the absence of growth factors or serum (24, 48 and 72 h) were centrifuged and washed once in PBS. They were suspended in a 1.5 ml solution containing Triton-X 100 0.1%, NaCitrate 0.1%, and propidium iodide 50 mg/ml (Sigma, Saint Quentin Fallavier, France) in polypropylene tubes at 4°C overnight. The samples were analyzed the following day using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA). Apoptotic nuclei appeared to be easily distinguishable and quantifiable by this assay due to high side scatter signal generated by the condensed nuclear chromatin.
Results
BCR-ABL expression in different UT-7 transfectant clones
As shown in Figure 1 , a representative Western blot analysis demonstrated the presence of BCR-ABL expression in all UT-7 transfectant clones obtained by either MPZen-p210 (UT-7/9 and UT-7/11) or MSCV p210 gene transfer (UT-7 E8, F1, G6). Differences of expression are, however, clear between these clones with very high levels of BCR-ABL protein in UT-7/9 and UT-7/11 clones and variable but much lower levels of BCR-ABL expression in MSCV p210 clones. In contrast, the endogenous levels of ABL protein remained identical in all clones, indicating that UT-7/9 and UT-7/11 were accumulating very high levels of BCR-ABL protein (Figure 1 ). The ratio of the chimeric BCR-ABL protein over the endogenous c-ABL protein (BCR-ABL:c-ABL ratio) in these two latter clones was 18.9 and 14.3, respectively, whereas in the other three clones this ratio remained between 1 and 1.5 (UT-7/E8:1.3; UT-7/G6.1.5; and UT-7/F1.1). The serial Western blot analyses (n = 7) have demonstrated stable levels of BCR-ABL in all clones except clone E8 in which a progressive increase of BCR-ABL protein was seen (Figure 1) . When compared to the initial E8 (E8-1) clone, the 'late' E8 clone (E8-2) was found to have a BCR-ABL:c-ABL ratio of 11 ( Figure 1) . Interestingly, this clone became progressively independent of GM-CSF for its growth (see below). All other 13 MSCV-transfected UT-7 clones selected in the presence of GM-CSF were also found to express low levels of BCR-ABL (data not shown). These marked differences in BCR-ABL expression allowed us to investigate the role of BCR-ABL in the proliferation of UT-7 cells in response to growth factors. Figure 2 shows the results of thymidine proliferation data on the BCR-ABL clones grown on GM-CSF and upon GM-CSF deprivation. The UT-7/9 and UT-7/11 clones could not be taken into account in that comparison due to their selection in the absence of GM-CSF. The parental UT-7 cells (Figure 2 ) and the UT-7 cells transfected with the MSCV-Neo vector alone (data not shown) remained totally dependent on GM-CSF for their growth. As can be seen in Figure 2 , all clones selected in the presence of GM-CSF (UT-7 E8, F1 and G6) showed significant mortality at 48 and 72 h upon GM-CSF deprivation. However, these clones were only partially growth factor-dependent. Indeed, persistent viability was observed upon growth factor deprivation which induced complete mortality of the parental cell line in 48-72 h (Figure 2 ). GM-CSF induced a strong proliferative response in all BCR-ABL clones with low levels of BCR-ABL protein as it did in the parental UT-7 cells (Figure 2 ) and the MSCV-Neo-transfected UT-7 clones (data not shown). The UT-7/E8-2 subclone showed almost complete GM-CSF independence with persistence of a modest response to GM-CSF (n = 8) (Figure 2) . Thus, these results suggested that low-level BCR-ABL expression was not sufficient to induce total growth factor independence in the UT-7 cell line and that the progressive increase of BCR-ABL expression was accompanied by progressive growth factor independence.
BCR-ABL expression is not sufficient to induce a complete growth factor-independent phenotype
We next tested the proliferative responses of our high-and low-level BCR-ABL-expressing clones to Epo, SCF and Tpo. None of these cytokines support the proliferation of the parental UT-7 cells. As expected, our two clones, UT-7/9 and UT-7/11, with total growth factor independence had no further proliferative response when cultured in the presence of Epo, SCF and TPO. In all clones with low levels of BCR-ABL such as UT-7/G6 (Figure 3 ) no specific proliferative response could be elicited to the above cytokines except for SCF which induced a moderate proliferative response in this clone only (Figure 3) . Similarly, in the E8-2 clone with progression to high BCR-ABL expression, no Epo, SCF or TPOspecific proliferative response could be documented (data not shown).
Figure 1
Western blot analysis of high-and low-level BCR-ABL-expressing clones. The parental UT-7 cells and the U937 cell line were used as controls. The intensity of the endogenous ABL band (145 kDa) was used as an internal control to assess the BCR-ABL:c-ABL ratio in each clone. (UT-7/9:18.9; UT-7/11:14.3; UT-7/E8:1.3; UT-7/G6.1.5; UT-7/F1:1).
Figure 2
Growth patterns of UT-7 clones expressing high and low levels of BCR-ABL protein in response to GM-CSF (10 ng/ml) as determined by 3 H-thymidine proliferation assay. Both UT-7/9 and UT-7/11 clones show a high proliferation rate with or without GM-CSF whereas E8-1, F1 and G6 clones expressing low levels of BCR-ABL continue to respond to GM-CSF while showing partial GM-CSF independence. The progression of the E8-2 subclone to almost complete GM-CSF independence correlated with increased BCR-ABL expression.
Figure 3
Comparative growth patterns of high-and low-level BCR-ABL-expressing UT-7 clones in response to GM-CSF, Epo, SCF and TPO in a 48 h 3 H-thymidine proliferation assay. UT-7/9 and UT-7/11 show a maximally spontaneous proliferative rate with no evidence of additional response to any of the cytokines. The representative low-level BCR-ABL-expressing G6 clone does not exhibit any significant proliferation in the presence of Epo and TPO but shows a modest proliferative response to SCF. The UT-7 parental cells exhibited no proliferative response in the absence of GM-CSF or in the presence of TPO.
Leukemia
Tumorigenicity of UT-7-BCR-ABL clones correlates with BCR-ABL protein levels
In order to determine if there was a correlation between the in vitro growth and the BCR-ABL protein levels, we injected BCR-ABL-expressing UT-7 clones into nude mice. As can be seen in Table 1 , the parental cell line was unable to form any visible subcutaneous tumor in mice. Similarly, none of the low-level BCR-ABL-expressing clones were able to induce any tumor in nude mice after several weeks of observation. However, both UT-7/9 and UT-7/11 clones expressing very high levels of BCR-ABL protein induced aggressive tumors appearing 2-3 weeks after injection of 2 × 10 6 cells ( Table 1 ). The E8-1 clone with low levels of BCR-ABL was not tumorigenic whereas the E8-2 subclone was tumorigenic in nude mice, inducing, however, less aggressive tumors than those obtained with injection of UT-7/9 and UT-7/11. The tumors analyzed by Western blots showed high levels of BCR-ABL similar to those found in the parental UT-7/9, UT-7/11 and UT-7/E8-2 (data not shown). These results confirmed the presence of a positive correlation between the in vivo behavior of tumors and BCR-ABL expression.
The anti-apoptotic effect of BCR-ABL requires high levels of BCR-ABL expression
In order to compare the anti-apoptotic function of BCR-ABL protein in different UT-7 clones expressing high and low levels of BCR-ABL, different apoptotic stimuli (serum deprivation, GM-CSF deprivation and etoposide) were used. Upon GM-CSF deprivation for 48 h, a mean value of 70% of apoptotic nuclei was observed in the parental cell line. Similarly, there was no resistance to apoptosis induced by GM-CSF deprivation in the UT-7 cells transfected with MSCV-Neo vector alone (data not shown). As expected, both UT-7/9 and UT-7/11 clones selected in the absence of GM-CSF showed no evidence of apoptosis upon GM-CSF deprivation (Figure 4) . In contrast, all three MSCV p210 clones expressing low levels of BCR-ABL showed an intermediate apoptotic response with mean values of apoptotic nuclei between 30% and 50%. Similarly, the E8-2 subclone of UT-7-E8 was more resistant to GM-CSF deprivation than the parental E8 clone expressing low levels of BCR-ABL. These observations correlated therefore with the partial growth factor-independent behavior of the low-level BCR-ABL-expressing clones (Figure 2) .
Upon serum deprivation, similar amounts of apoptotic UT-7/P: parental UT-7 cells. Mice were injected with 2 × 10 6 cells from the corresponding clones with high (UT-7/9, UT-7/11, UT-7/E8-2) and low level (UT-7/F1, UT-7/G1, UT-7/E8-1) BCR-ABL expression and the frequency of subcutaneous tumor formation was monitored at the indicated times.
nuclei were documented in both parental cell line and lowlevel BCR-ABL clones whereas both UT-7 clones hyperexpressing BCR-ABL remained non-apoptotic over 48 h (data not shown). Similarly, when cells were treated with increasing doses of etoposide for 20 h, the low-level BCR-ABL expressing UT-7/E8, G6 and F1 were not protected from apoptotic cell death whereas UT-7/9 and UT-7/11 with the highest BCR-ABL expression were able to survive ( Figure 5 ). The behavior of the E8 cell line with high levels of BCR-ABL (E8-2) was clearly different from that observed in the E8 clone with low levels of BCR-ABL (E8-1). As can be seen in Figure 5 , the E8 cell line which progressively acquired an increased BCR-ABL protein level also showed an increased resistance to etoposideinduced apoptosis, especially in the presence of low doses of this drug. This protective effect against apoptosis elicited by the high level of BCR-ABL protein expression was further demonstrated using a PARP-cleavage assay. As can be seen in Figure 6 , parental cells treated with 30 g/ml of etoposide for 6 h underwent a significant PARP cleavage as evidenced by the appearance of an 89 kDa band ( Figure 6 ). During the same period of time, UT-7/9 cells did not show any significant PARP cleavage upon etoposide treatment whereas the F1 clone with a low level of BCR-ABL expression exhibited an intermediate amount of PARP cleavage suggesting a positive correlation between the amount of BCR-ABL protein and the anti-apoptotic potential of BCR-ABL. These findings were also confirmed at earlier time-points and at smaller doses of etoposide when cells were treated with 2, 4, 6 and 8 g/ml of etoposide (data not shown).
Discussion
In this work, we studied the effects of different levels of BCR-ABL protein on the survival and proliferation of a growth factor-dependent pluripotent human cell line. Both BCR-ABL vectors MP-ZEN and MSCV-p210 allowed BCR-ABL expression in UT-7 cells. However, the two clones with very high levels of BCR-ABL protein were obtained after using MP-ZEN p210 retrovirus-mediated gene transfer and selection of transduced cells in the absence of GM-CSF. This selection is probably responsible for the increased BCR-ABL expression in these clones whereas BCR-ABL protein levels in the clones obtained using MSCV-p210 and selected in the presence of both G418 and GM-CSF remained relatively low. Both MP-ZEN and MSCV LTR's contain sequences derived from the myeloproliferative sarcoma virus and this substitution has pre-
Figure 4
Quantitative analysis of apoptosis in parental UT-7 cells and in UT-7-BCR-ABL clones in response to GM-CSF deprivation for 24, 48 and 72 h. All UT-7 parental cells undergo apoptotic cell death in the absence of GM-CSF in 72 h. High-level BCR-ABL protein-expressing UT-7/9 and UT-7/11 clones remain non-apoptotic during this period of time whereas low-level BCR-ABL-expressing E8, G6 and F1 clones show an intermediate type of apoptotic response. The E8-2 subclone of E8-1 showed a significant resistance to GM-CSF deprivation-induced apoptosis.
Figure 5
Quantitative analysis of apoptosis in the parental UT-7 cells and the UT-7-BCR-ABL clones in response to etoposide. All clones were cultured in triplicate in the presence of GM-CSF and variable concentrations of etoposide for 20 h before performing a propidium iodide analysis of apoptotic nuclei using flow cytometry (n = 3).
Figure 6
Comparative analysis of polyadenosyl ribophosphate (PARP) cleavage in parental UT-7 cells as well as in UT-7/9 and UT-7/F1 by Western blotting. 10 6 cells were grown in the absence or presence of etoposide (VP-16) for 20 h and total protein extracts were immunoblotted using an anti-PARP antibody. The cleavage product of 89 kDa (p89) is clearly seen in the parental UT-7 cells whereas the UT-7/9 clone is resistant to PARP cleavage during the same period of time. The low-level BCR-ABL-expressing UT-7/F1 shows an intermediate cleavage pattern.
viously been shown to lead to improved gene expression in hematopoietic cells as compared to retroviral vectors based on Moloney murine retrovirus LTRs. 20 The presence of Neo-R sequences in the MSCV-p210 vectors could lead to reduced BCR-ABL expression when cells are selected in the presence of G418, through a transcriptional silencing mechanism 21 as opposed to the MP-ZEN p210 vector where BCR-ABL is the only gene expressed through the 5Ј LTR. 17 The practical result of the use of the two different BCR-ABL vectors and/or the cell selection system was the obtention of clones with low and high levels of BCR-ABL expression in the pluripotent human cell line UT-7.
BCR-ABL is the oncogene responsible for the initiation of human chronic myelogenous leukemia. 22 During the last few years important progress has been made in the understanding of signal transduction pathways activated by BCR-ABL. [23] [24] [25] [26] [27] None of the signalization pathways has so far been convincingly linked with the major experimental phenotypes observed in cells expressing BCR-ABL, such as maintenance of differentiation potential during the chronic phase, increased cycling behavior in long-term culture 28 or inhibition of apoptosis. 7, 8 The demonstration of the anti-apoptotic potential of the BCR-ABL protein in both murine and human growth factor-dependent cell lines allowed important insights to be made in the understanding of leukemia progression with an assumption that inhibition of apoptosis could favor the appearance of secondary transforming events. 29 In some cell transformation models, a temperature-sensitive mutant of BCR-ABL has been used showing that the tyrosine kinase activity of BCR-ABL was crucial for cell survival. 13 However, none of these studies have determined the potentially differential effects of BCR-ABL in the same cell line according to the level of expression. The use of Western blot technology to detect and quantify BCR-ABL protein has been shown to be clinically useful in patients with CML, either at diagnosis 30 or after therapy 31 with a clear correlation between the percentage of Ph1+ metaphases. 30 However, data with regard to the anti-apoptotic effects of BCR-ABL in primary patient samples are controversial. The increased resistance of primary CML progenitors to apoptosis induced by growth factor deprivation 8 was not confirmed by other studies, which found no difference between normal and CML progenitors in response to several apoptotic stimuli.
9,10 A single study using fetal calf serum deprivation as an apoptotic stimulus, also showed no difference of behavior between normal control cells and chronic phase neutrophils whereas CML neutrophils from accelerated phase had significant inhibition of apoptosis in the same conditions. 32 These results are in keeping with the data showing an increase of BCR-ABL RNA when CML patients progress from chronic towards an acute phase. 33 The heterogeneity of patient samples and the potential differences of BCR-ABL protein expression, which varies from one patient (and probably from one hematopoietic cell) to another, could explain discordant findings obtained with regard to the inhibition of apoptosis in primary patient samples. 9, 10 Our model distinctly shows that: (1) BCR-ABL protein expression in a human hematopoietic cell line is not sufficient to induce growth factor independence; and (2) the anti-apoptotic effect of BCR-ABL is fully operational only when BCR-ABL is expressed at high levels. Our data confirm, therefore, for the first time in pluripotent human cells, the results obtained by Pierce et al 34 in the murine FDCP-mix cell line in which the tyrosine kinase activity of BCR-ABL was found to be compatible with growth factor dependence and differentiation ability.
In our studies, the UT-7 clones with low levels of BCR-ABL also showed improved resistance to growth factor deprivationinduced apoptosis whereas their apoptotic response to etoposide remained almost undistinguishable from that obtained in the parental cells ( Figure 6 ). Interestingly, in one clone (UT7-E8) we were able to observe a progressive increase of BCR-ABL protein levels upon the appearance of growth factor independence which also unsurprisingly correlated with the appearance of an increased resistance to etoposide. The behavior of this clone with regard to apoptosis and growth factor independence was found to be intermediate between the low-level BCR-ABL-expressing clones E8-1, F1 and G6 and the high-level BCR-ABL-expressing UT-7/9 and UT-7/11 essentially by the fact that the E8-2 clone still remained slightly sensitive to the proliferative effect of GM-CSF. We obviously cannot incriminate the very high BCR-ABL protein level in the appearance of a total growth factor independence in the two clones UT-7/9 and UT-7/11 but these two clones with very high levels of BCR-ABl represent an interesting acute phase model of CML as a progressive increase in BCR-ABL RNA levels has been shown in patients progressing towards the acute phase 33 whereas our clones with low levels of BCR-ABL could reflect the behavior of CML cells at an earlier phase of the disease. However, it should be pointed out that we cannot rule out the possibility that the differential behavior of high-level BCR-ABL-expressing clones is due to the occurrence of additional genetic events as compared to low-level BCR-ABL-expressing clones. Similarly, it is difficult to extrapolate data from cell lines to primary CML samples and the determination of the role of high levels of BCR-ABL protein expression in the phenotype observed in CML patients in different stages of their disease must await studies looking at BCR-ABL protein levels in primary progenitors.
In the experimental setting, complete growth factor independence that is obtained after BCR-ABL gene expression in several cell lines 1,2 including an autocrine GM-CSF secretion 3 could be present only when significant amounts of BCR-ABL are present inside the cell. In our two clones with the highest levels of BCR-ABL, we found no evidence of autocrine growth although very small amounts of GM-CSF, IL-6 and Epo were demonstrated in the culture media (data not shown). In both of these clones we showed evidence of constitutive STAT5 activation as this could also be shown in other hematopoietic cell lines after BCR-ABL gene transfer. 35 The ability to test the behavior of different BCR-ABL clones exhibiting different amounts of BCR-ABL protein in the same cellular background using an in vivo nude mice model is also important for the development of an in vivo therapeutic model. Our results clearly show a positive correlation between BCR-ABL expression and the aggressivity of tumors in nude mice. Recently, using the Ba/F3 cell line, it has been shown that there was also a correlation between the levels of BCR-ABL protein expressed and resistance to apoptosis.
14 However, all Ba/F3 clones analyzed showed rapid growth factor independence as opposed to our findings in human hematopoietic UT-7 cells in which we demonstrate that BCR-ABL expression alone is not sufficient to induce the growth factor-independent behavior. To our knowledge, this is the first demonstration that BCR-ABL expression by itself is not 'transforming' in the sense of acquisition of growth factor independence in human hematopoietic cells and that the anti-apoptotic effect of BCR-ABL might therefore prevail over its proliferative effect. The same conclusion was previously obtained in a murine hematopoietic cell line, using a temperature-sensitive mutant of BCR-ABL. 36 These findings might have pathophysiological impli-cations with regard to the heterogeneity observed in duration of chronic phase which could be influenced by the amount of BCR-ABL protein. They also have implications with regard to the recent demonstration of BCR-ABL expression in the peripheral blood of healthy individuals. 37 It is conceivable that BCR-ABL, with its anti-apoptotic potential prevailing over its proliferative effect is responsible for the maintenance of a clone for several years, and according to the hierarchical type of the progenitor where this event first occurred, induce the appearance of CML in some of these individuals.
In conclusion, our model provides data and supports the hypothesis that the levels of BCR-ABL protein inside the transformed cell is an important factor in determining the phenotype obtained with regard to growth factor response and inhibition of apoptosis. In the UT-7 model, the initial effects of low levels of BCR-ABL expression are subtle and include partial growth factor independence which translates into a modest inhibition of apoptosis upon growth factor deprivation whereas cells remain sensitive to the apoptotic stimuli provided by chemotherapeutic agents such as etoposide. With the appearance of higher levels of BCR-ABL, cells achieve complete growth factor independence as well as drug resistance which also characterizes human CML in its acute phase. The UT-7 BCR-ABL cells might be helpful for further characterization of these events.
